Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Parkinson’s Foundation and Melvin Yahr International Parkinson’s Disease Foundation Announce Merger

Parkinson’s Foundation Establishes ‘Dr. Melvin Yahr Research Award’ to Fund Neurology Fellows, Promote Leadership Diversity in Parkinson’s Research

MIAMI & NEW YORK — The Parkinson’s Foundation today announced its merger with the Melvin Yahr International Parkinson’s Disease Foundation. The foundation, based in New York, is named after Melvin D. Yahr, M.D., a pioneer in Parkinson’s disease (PD) research whose work led to the adoption of levodopaThe medication most commonly given to control the movement symptoms of Parkinson’s, usually with carbidopa. It is converted in the brain into dopamine. as a revolutionary new Parkinson’s treatment.

“The Parkinson’s Foundation is honored to pay tribute to the many contributions Dr. Melvin Yahr has made to the Parkinson’s community,” said John Kozyak, Esq., chairman of the Parkinson’s Foundation board of directors. “We are proud to continue our long-standing tradition of supporting the next generation of Parkinson’s researchers.”

The Parkinson’s Foundation will honor Dr. Yahr’s legacy by establishing the “Dr. Melvin Yahr Research Award” to promote leadership diversity in Parkinson’s research. The two-year grant will be awarded to one neurology fellow every other year with the intent to fund individuals who have been underrepresented in Parkinson’s research at academic institutions. The foundation also will establish individual “Congress Awards” to help cover travel costs to attend the Congress of the International Association of Parkinsonism and Related Disorders - World Federation of Neurology.

“Dr. Yahr was an expert on Parkinson’s disease whose name is known around the world,” said Lice Ghilardi, M.D., president of the Melvin Yahr International Parkinson’s Disease Foundation. “He has launched many careers in neurology and we are happy to carry on this tradition by funding scholars in his name.”

Dr. Yahr (1917-2004) graduated from New York University and its medical school. He served as Professor of Neurology and Associate Dean of Columbia University’s medical school. With funding from William Black to construct a new research building at Columbia, Dr. Yahr was appointed head of Columbia’s Parkinson’s research team and Scientific Director of the Parkinson’s Disease Foundation, which was founded in 1957 by Mr. Black and has since merged with the National Parkinson Foundation to become the Parkinson’s Foundation.

One of Dr. Yahr’s major career achievements was the development of the Hoehn-Yahr scale in 1967, the first widely used PD rating scale that is still in use today. He published more than 300 scientific papers and helped found the specialty of movement disorders.

The merger is subject to the approval of the Attorney General or the Supreme Court of the State of New York.

About the Parkinson’s Foundation

The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience, and passion of our global Parkinson’s community. For more information, visit www.parkinson.org, or call 1-800-4PD-INFO (473-4636).

About Parkinson’s Disease

Affecting an estimated one million Americans and 10 million worldwide, Parkinson’s disease is the second-most common neurodegenerative disease after Alzheimer’s and is the 14th-leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression A mood disorder whose symptoms can include a persistent sad or empty mood, feelings of hopelessness or pessimism, irritability and loss of interest or pleasure in previously enjoyable activities. and anxiety A feeling of nervousness, worried thoughts and physical distress.). There is no cure for Parkinson’s and 60,000 new cases are diagnosed each year in the United States alone.

Thursday, October 26, 2017
New Study Shows 1.2 Million People in the United States Estimated to be Living with Parkinson’s Disease by 2030
Tuesday, July 10, 2018

Parkinson’s Foundation Reveals Most Comprehensive Estimate of
Parkinson’s Prevalence in North America since the 1970’s

Parkinson’s Foundation Elects Howard D. Morgan Chairman of the Board
Tuesday, June 26, 2018

MIAMI & NEW YORK — June 26, 2018 — The Parkinson’s Foundation today announced the election of Howard D. Morgan as chairman of its board of directors. Mr. Morgan, who previously served as the Vice Chair of the nonprofit organization’s board, is a Partner and the Senior Managing Director of Argand Partners in New York.

Parkinson’s Foundation Announces Five New Members of its People with Parkinson’s Advisory Council
Wednesday, June 13, 2018

NEW YORK & MIAMI — June 13, 2018 — The Parkinson’s Foundation today announced five new members of its People with Parkinson’s Advisory Council.

The Parkinson’s Foundation 2018 Gala in New York City Tuesday, May 8, 2018
Monday, May 14, 2018

The Parkinson’s Foundation 2018 Gala was held at Cipriani 25 Broadway in New York City on Tuesday, May 8, 2018.

Parkinson’s Foundation Adds Alison Herman to its Board of Directors
Tuesday, May 8, 2018

MIAMI – May 9, 2018 – The Parkinson’s Foundation today announced the election of Alison Herman to its board of directors. Herman is senior counsel at Southern Glazer’s Wine & Spirits, a company which has generously supported Parkinson’s Foundation fundraisers.

Statement on Nuplazid Drug
Tuesday, April 10, 2018

On 4/9/18, CNN published an article on the FDA-approved drug, Nuplazid, used to treat hallucinations and psychosis A broad medical term used to describe a loss of contact with reality that involves hallucinations and/or delusions. in Parkinson’s disease.

Parkinson’s Foundation Adds John D. Thomopoulos to its Board of Directors
Monday, March 19, 2018

MIAMI & NEW YORK – March 19, 2018 – The Parkinson’s Foundation today announced the election of John D. Thomopoulos to its board of directors. Thomopoulos is a partner at Ernst & Young.

In Memory of Edythe Kay Marsa
Monday, March 12, 2018

The Parkinson’s Foundation mourns the loss of emeritus board member, Edythe (Edy) Kay Marsa. From 1993 to 2014, she was a member of the Foundation’s board of directors and served on several committees. Edy is survived by her husband William Marsa, who founded the Herbert Kay Parkinson Chapter in honor of her first husband who passed away due to complications from Parkinson’s disease.

Parkinson’s Foundation Announces New Genetic Initiative Connecting Parkinson’s Genetic Data with Clinical Care
Tuesday, March 6, 2018

MIAMI & NEW YORK—March 6, 2018—The Parkinson’s Foundation today announced a new initiative offering genetic testing and counseling to Parkinson’s patients within its Center of Excellence network.

Delegates From The Parkinson’s Community Converge On Capitol Hill To Advocate For Critical Research Funding
Monday, March 5, 2018

—2018 Parkinson’s Policy Forum Co-Sponsored by the Parkinson’s Foundation and the Michael J. Fox Foundation for Parkinson’s Research—

Pages

mail icon

Subscribe here to get the latest news on treatments, research and other updates.